Our blogs explain health conditions and clinical research in a way that is easy to follow, so readers can feel more informed
Drug Hope for Dementia and Stroke
Scientists have uncovered a potential approach to treat one of the commonest causes of dementia and stroke in older people. Studies with rats found the treatment can reverse changes in blood vessels in the brain associated with the condition, called cerebral...
Melanoma Results from Loss of Cilia
Most cells in the human body have a cilium, a slender cell protuberance that picks up signals from the cell’s external environment. Researchers at the University of Zurich have now shown that these fine sensory antennae play a key role in...
Experimental Drug Stops Parkinson’s Disease in Mice
Johns Hopkins researchers say they have developed an experimental drug, similar to compounds used to treat diabetes, that slows the progression of Parkinson’s disease itself — as well as its symptoms — in mice. In experiments performed with cultures of human...
Achaogen wins FDA approval for new antibiotic Zemdri
Achaogen got some anticipated good news Tuesday with an FDA nod for its high-powered antibiotic Zemdri, but it wasn’t an unqualified win. Zemdri will make its debut as a treatment for drug-resistant urinary tract infections with a black-box warning, and it...
ADA: J&J’s Invokana and rivals cut heart attack hospitalizations without increasing amputation risk
ORLANDO, Fla.—Johnson & Johnson’s Invokana is alone in the class of SGLT2 diabetes drugs in carrying a boxed warning detailing amputation risks, but a new real-world analysis of more than 700,000 patients found the medication and other SGLT2 drugs lowered heart attack hospitalizations...
Success of Blood Test for Autism Affirmed
One year after researchers published their work on a physiological test for autism, a follow-up study confirms its exceptional success in assessing whether a child is on the autism spectrum. A physiological test that supports a clinician’s diagnostic process has the...
Standard Myelofibrosis Drug Awakens “Dormant” Lymphoma
Standard Myelofibrosis Drug Awakens “Dormant” Lymphoma Source: https://abm-website-assets.s3.amazonaws.com/biosciencetechnology.com/s3fs-public/styles/hero/public/featured_image/2018/06/bone%20marrow_Shutterstock_featured.jpg?itok=ub83q-FK Most patients with myelofibrosis, a rare chronic disorder of the hematopoietic cells of the bone marrow, benefit from drugs from the JAK2 inhibitor class: symptoms are relieved, survival extended and general quality-of-life enhanced....
FDA Clears Wearable Device to Treat Opioid Addiction
DyAnsys Inc. announced that the U.S. Food and Drug Administration has cleared its auricular neurostimulation device, Drug Relief, to be used as an aid to reduce the symptoms of opioid withdrawal without narcotics. Drug Relief is available now for providers to prescribe...
Dementia Can be Caused by Hypertension
A new study in Cardiovascular Research, published by Oxford University Press, indicates that patients with high blood pressure are at a higher risk of developing dementia. This research also shows (for the first time) that an MRI can be used to detect...
Study: Specific Brain Circuits Could Unlock New Psychiatric Treatments
A McLean Hospital scientific team’s comprehensive analysis of recent research into how the brain shapes responses to cognitive and emotional challenges have revealed the potential for new brain treatments for psychiatric conditions that target specific brain circuits. The detailed review, “An...
How the Body Evens Out its Immune System
In your body, blood stem cells produce approximately 10 billion new white blood cells, which are also known as immune cells, each day. Even more remarkably, if some of these blood stem cells fail to do their part, other blood stem...
Maintenance Chemotherapy Extends Life for Children With a Rare Cancer
A new chemotherapy strategy improves cure rates for children with rhabdomyosarcoma (a rare cancer of the muscle tissue) who are at high risk for cancer recurrence. In a randomized phase III clinical trial, adding six months of low-dose maintenance chemotherapy after...